Neffy®, an FDA-approved intranasal epinephrine spray, demonstrates bioequivalence to injectable epinephrine for anaphylaxis treatment in patients weighing ≥30kg, potentially reducing barriers to rapid intervention.

The study found no evidence that any of 25 routine clinical laboratory values provide a reliable biomarker of prior infection, PASC, or specific PASC clusters.

Recent findings suggest that a slow up-dosing strategy in peanut oral immunotherapy for young children may offer a safer and more effective approach to managing peanut allergies.

In a phase 3 trial, oral sebetralstat demonstrated a median time to beginning of symptom relief of 1.61 hours for the 300 mg dose and 1.79 hours for the 600 mg dose, compared to 6.72 hours for placebo in hereditary angioedema attacks.

Apple oral immunotherapy allowed patients to tolerate an entire apple after just 39 days on average, with potential cross-tolerance to other Rosaceae fruits.

A comprehensive analysis of more than 2 million hospitalizations across 115+ US VA medical centers has revealed that 57% of patients treated for pneumonia experienced discordances between their initial and discharge diagnoses.